Oxygen Biotherapeutics Video Library

News & Events

Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program


Tuesday, March 4, 2014 5:00 am PST
Dateline:
MORRISVILLE, N.C.

Public Company Information:
NASDAQ:OXBTUS69207P2092


Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has been notified by the U.S. Food and Drug Administration (the “FDA”) that the agency has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte®. Lifting of the clinical hold clears the company to proceed with the clinical development program in the US. The FDA communicated this information to the company during a conference call with the FDA on Friday, February 28, 2014. Written confirmation of the FDA’s decision is expected to be received within 30 days. more..

Quick Links

Oxygen, Elastin, and Collagen – Dr. Gerald Klein talks about why oxygen is important for skin.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Oxycyte and Decompression Sickness – Dr. Gerald Klein explains Decompression Sickness.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Oxycyte Ischemia – Dr. Gerald Klein explains ischemia

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Oxycyte Traumatic Brain Injury – Dr. Gerald Klein explains What is severe traumatic brain injury? Can Oxycyte help?

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player